POLB 001 patent granted in South Africa

Poolbeg Pharma PLC

30 June 2026

 

Poolbeg Pharma plc

POLB 001 patent granted in South Africa for the treatment or prevention of hypercytokinemia and severe influenza

Patent decision strengthens Poolbeg's intellectual property portfolio

30 June 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces it has received notification of the official decision to grant Poolbeg's Immunomodulator II patent in South Africa, providing protection for POLB 001 for the prevention of hypercytokinaemia and severe influenza until December 2038.

POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the prevention of cancer immunotherapy-induced Cytokine Release Syndrome ("CRS") and severe influenza. POLB 001 holds the potential to address significant unmet needs affecting patients and healthcare systems globally.

Poolbeg has a robust portfolio of patents in place covering p38 MAP kinase inhibitors for the treatment of severe influenza; and for POLB 001 for the prevention of hypercytokinemia. Additional patent applications have been filed to strengthen and complement Poolbeg's POLB 001 patent portfolio, particularly for cancer immunotherapy-induced CRS. Developing a strong intellectual property portfolio remains a key priority for Poolbeg, enhancing POLB 001's value and appeal to potential partners.

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg, commented: "This latest patent grant reflects our commitment to further strengthen POLB 001's global IP portfolio, enhancing its value and attractiveness to prospective partners. POLB 001 holds the potential to significantly benefit patients and healthcare systems globally across multiple disease areas, and this patent represents another step forward in our mission to positively impact the lives of patients."

Enquiries

Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O'Connell, CFO	[phone] [e-mail]
Cavendish Capital Markets Ltd (NOMAD & Joint Broker) Geoff Nash, Trisyia Jamaludin (Corporate Finance) Nigel Birks (Life Science Specialist Sales) Harriet Ward (ECM)	[phone]
Shore Capital Stockbrokers Ltd (Joint Broker) David Coaten, Harry Davies-Ball (Corporate Advisory) Malachy McEntyre (Corporate Broking)	[phone]
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist	[phone]
Optimum Strategic Communications Nick Bastin, Katie Flint, Elena Bates	[phone] [e-mail]

About Poolbeg Pharma plc 

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs. 

Stay updated: Website | Sign up for RNS alerts | Presentation | X | LinkedIn

Forward-Looking Statements

This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.

 

END